Background-Currently, there are no specific therapies available to treat cardiac dysfunction caused by sepsis and other chronic inflammatory conditions. Activation of toll-like receptor 4 (TLR4) by lipopolysaccharide (LPS) is an early event in Gram-negative bacterial sepsis, triggering a robust inflammatory response and changes in metabolism. Peroxisome proliferator-activated receptor-␥ coactivator-1 (PGC-1) ␣ and ␤ serve as critical physiological regulators of energy metabolic gene expression in heart. Methods and Results-Injection of mice with LPS triggered a myocardial fuel switch similar to that of the failing heart:
Clinical Perspective on p 482
The heart's high-capacity, ATP-generating mitochondrial system is under the control of a gene regulatory circuit. 4 Members of the nuclear receptor transcription factor super-family, including peroxisome proliferator-activated receptors (PPARs) and the estrogen-related receptors (ERRs), control the expression of many genes involved in mitochondrial energy transduction pathways including fatty acid ␤-oxidation (FAO), the electron transport complex, and oxidative phosphorylation. 5, 6 The nuclear respiratory factors [NRF-1 (Nrf1) and NRF-2 (Gabpa)] coordinately regulate transcription of nuclear and mitochondrial genes involved in electron transport and mitochondrial DNA replication. 7 The expression of several of these genes has been shown to be suppressed by inflammation at the transcriptional level; however, the upstream signals and functional relevance of this response are unclear. 8, 9 The activity of the PPARs, ERRs, and NRFs is orchestrated by PGC-1␣ and ␤ (Ppargc1a and b), inducible, cardiac-enriched transcriptional coactivators. 10, 11 Targeted disruption of the PGC-1␣ and PGC-1␤ genes in mice causes mitochondrial dysfunction and heart failure, evidence that deactivation of this pathway can lead to myocyte contractile dysfunction. 12, 13 The PGC-1 gene regulatory circuit is also deactivated in heart failure through mechanisms that have not been defined. 14 Inflammatory signaling has been reported to both augment or suppress the expression or activity of the PGC-1 coactivators. 8, [15] [16] [17] The interpretation of these studies is further confounded by the lack of corroborative functional and metabolic data. Thus, questions remain regarding the regulation and physiological impact of the PGC-1 coactivators during times of inflammatory stress.
The inflammatory response and left ventricular dysfunction induced by lipopolysaccharides (LPS) is mediated in large part by the host molecule toll-like receptor 4 (TLR4). 18 Interestingly, TLR4 signaling is also important in other cardiovascular diseases including ischemia-reperfusion injury and cardiac hypertrophy. 19 -21 Activation of TLR4 leads to the nuclear translocation of nuclear factor (NF)-B, which drives the expression of inflammatory cytokines. 22 We hypothesized that TLR4-mediated inflammation could serve as the upstream signal that modulates myocardial energy metabolism in sepsis. Our data demonstrated that the acute administration of LPS recapitulated aspects of the metabolic reprogramming known to occur in the failing heart, including downregulation of PGC-1␣ and PGC-1␤ gene expression, leading to reduced mitochondrial substrate flux and lipid accumulation. The suppression of PGC-1 gene expression was shown to occur through a TLR4 and NF-Bdependent mechanism. Restoration of PGC-1 coactivator activity in cardiac myocytes during acute inflammation reversed LPS-induced alterations in cardiac fuel metabolism in vitro and in vivo.
Methods

Animal Experiments and Generation
Adult (age, 8 to 12 weeks) male C57BL/6 mice were obtained from Jackson Laboratory. TLR4 and TLR2 knockout mice (C57BL/6 background) were purchased from Oriental BioService, Inc (Japan). Adult mice (8 to 16 weeks of age) were used for experiments. To generate the TRE-PGC-1␤ line, Ppargc1b cDNA was cloned into the pTRE-2 vector (Clontech), linearized with AatII and AseI, and injected into fertilized mouse eggs. Positive founders were identified by transgene-specific polymerase chain reaction, using the following primers: forward 5Ј-TCCGTGAGTTACCATTCTGAT-3Ј, Reverse 5Ј-GAGGAGACAATGGTTGTCAAC-3Ј. The TRE-PGC-1␤ mice were crossed to the MHC-rtTA 23 line to produce TRE-PGC-1␤ MHC-rtTA mice. TRE-PGC-1␤ MHC-rtTA mice (FVB background) were fed chow containing doxycycline (Research Diets C11300 -200i) ad libitum for 2 days. Mice (age, 10 to 16 weeks) were given intraperitoneal injections of 150 g (FVB) or 200 g (C57BL/6) of Escherichia coli 0111:B4 LPS (Sigma) resuspended in phosphatebuffered saline (PBS) or an equal volume of PBS alone. Injections were performed in the morning, and food was removed from all animals immediately after the injection to control for the anorexia induced by LPS.
All animal experiments were conducted in strict accordance with National Institutes of Health guidelines for humane treatment of animals and were reviewed by the Animal Studies Committee of Washington University School of Medicine.
Statistical analysis was performed with the use of GraphPad Prism 5. Two-way ANOVA with Bonferroni post test analysis or repeatedmeasures ANOVA with Bonferroni posttesting was used. The Student unpaired t test, using Microsoft Excel, was used for simple comparisons. See the figure legends for more detail.
An expanded Materials and Methods section, including all procedures used in this report, is available in the online-only Data Supplement.
Results
LPS Stimulation Suppresses Cardiac Mitochondrial Fatty Acid Oxidation Leading to Myocyte Lipid Accumulation
To assess the impact of inflammation on myocardial fuel metabolism, a sublethal dose of LPS was administered to adult male C57BL/6 mice. LPS stimulation led to rapid induction of myocardial cytokine gene expression, including tumor necrosis factor (TNF)␣, followed by an increase in the levels of mRNAs encoding macrophage chemoattractant protein 1[MCP1 (Ccl2)], interleukin 6 (IL-6), and nitric oxide synthase 2 (NOS2 or iNOS; Figure 1A ). Left ventricular fractional shortening was significantly decreased 6 hours after LPS injection, with recovery by 24 hours, consistent with observed transient myocardial inflammatory response ( Figure 1B ).
Fuel oxidation rates were assessed in working hearts isolated from mice 12 hours after injection of LPS or vehicle. LPS treatment resulted in significantly lower myocardial palmitate oxidation rates compared with vehicle-injected mice ( Figure 1C ). Glucose oxidation rates were low in both groups and probably were related to the fasting state of the animals, which increases expression of pyruvate dehydrogenase kinase 4, an enzyme that suppresses glucose oxidation ( Figure 1C ). Serum free fatty acid and triglyceride levels were increased 6 hours after LPS injection compared with control mice (1.17Ϯ0.06 mg/dL versus 1.58Ϯ0.07 mg/dL, PՅ0.05 and 115Ϯ6.8 mg/dL versus 148Ϯ8.7 mg/dL, PՅ0.05, respectively). Myocardial triglyceride levels were elevated after LPS injection as evidenced by oil red O staining of neutral lipids in cardiac myocytes and direct quantification ( Figure 1D ).
LPS-Triggered Activation of Inflammatory Pathways in the Cardiac Myocyte Results in Suppression of the PGC-1 Gene Regulatory Cascade
Given the regulatory role of PGC-1 coactivators in maintaining a high-capacity mitochondrial system, we next assessed the effect of LPS on the myocardial expression of the PGC-1␣ and PGC-1␤ genes. LPS injection led to a rapid downregulation of PGC-1␣ and PGC-1␤ mRNA levels, with PGC-1␤ being the most dramatically affected (reduced Ͼ90%; Figure 2A ). PGC-1␣ protein levels were also significantly diminished (Figure 2A Figure 1A ). Similar to the effects on PGC-1 coactivators, the expression of all of these metabolic genes was reduced at the mRNA level after LPS injection. In addition, expression of the PGC-1 target gene encoding the glucose transporter GLUT4 (Slc2a4) was also decreased by LPS instillation. Other genes involved in the regulation of FAO such as PPAR␤/␦ and the myocardial FA transporter CD36 (Cd36) were not differentially expressed in the inflamed myocardium (online-only Data Supplement Figure  1A ). These gene expression results are similar to those observed in the hearts of PGC-1␣ and PGC-1␤ double knockout mice, 13 supporting the concept that LPS-mediated inflammation leads to rapid deactivation of the PGC-1 metabolic gene regulatory circuit.
To assess whether the observed effects of LPS occur in cardiac myocytes independent of systemic alterations such as ventricular dysfunction, LPS stimulation experiments were conducted with primary neonatal rat cardiac myocytes in culture. The effects of LPS on metabolic gene expression paralleled that seen in the heart in vivo, including reduced expression of genes encoding PGC-1␣, PGC-1␤, PPAR␣, ERR␣, MCAD, and GLUT4 ( Figure 3A , 3B, and 3C). To determine whether the LPS-mediated suppression of PGC-1␣ gene expression involved transcriptional mechanisms, a mouse PGC-1␣ promoter luciferase reporter (PGC.Luc.2112) was used for transient transfection studies in cardiac myocytes. LPS reduced the activity of PGC.Luc.2112 by approximately 50% but activated an NF-B responsive control reporter ( Figure 3D ).
AMP-activated protein kinase (AMPK) is an energysensing kinase known to stimulate expression of the PGC-1␣ gene. 24, 25 To determine the effects of LPS on AMPK, the level of AMPK phosphorylation was determined after LPS stimulation. Phosphorylated AMPK was increased by LPS treatment arguing that AMPK is not upstream of the observed metabolic changes (online-only Data Supplement Figure 1B ).
TLR4 and NF-B Are Required for LPS-Mediated Suppression of PGC-1␣ and PGC-1␤ Gene Expression
To address whether the changes in PGC-1 coactivator expression were dependent on functional TLR4, LPS challenge experiments were conducted with wild-type, TLR4 Ϫ/Ϫ , and TLR2 Ϫ/Ϫ mice, followed by assessment of gene expression and myocardial triglyceride levels at 6 hours. The absence of TLR4 abolished LPS-induced downregulation of PGC-1␣ and significantly blunted the downregulation of PGC-1␤ ( Figure 4A ). The increase in serum and myocardial lipids was also attenuated in mice lacking TLR4 ( Figure 4A and data not shown). In contrast, TLR2 Ϫ/Ϫ mice behaved identically to wild-type animals. Similar results were obtained in cell culture using a specific inhibitor of TLR4 signaling, CLI95 26 ( Figure 4B ). Thus, TLR4 is an obligate component of the inflammatory and metabolic events induced by LPS in the myocardium.
NF-B is a key downstream target of TLR4 signaling. To determine the importance of NF-B activation in this system, cardiac myocytes were pretreated with a chemical inhibitor of I-kinase, Bay 11-7085. Compared with DMSO-treated control mice, Bay 11-7085 completely blocked the suppression of PGC-1␣ and PGC-1␤ expression after LPS stimulation ( Figure 4C ). As expected, Bay 11-7085 also decreased the expression of the NF-B-regulated cytokines, TNF␣, and IL-6 ( Figure 4C ). TNF␣, IL-6, and iNOS are induced by LPS in a TLR4 and NF-B-dependent manner and have all been implicated in sepsis-induced cardiodepression. 27, 28 To determine the role of TNF␣ and IL-6 in the suppression of PGC-1␣, we used inhibitory antibodies to block their biological activity. Neither inhibition of TNF␣ or IL-6 prevented the downregulation of PGC-1␣ by LPS (online-only Data Supplement Figure 2A and 2B). Cardiac myocytes were also pretreated with the iNOS inhibitor L-NIL which, despite preventing LPS-induced NO production, had no affect on PGC-1␣ gene expression (online-only Data Supplement Figure  2C ). Together, the data argue that TLR4 and NF-B are required for the suppression of PGC-1␣ expression by LPS; however, this effect is largely independent of TNF, IL-6, and NO.
Cardiac-Specific Induction of PGC-1␤ Reverses LPS-Triggered Suppression of Myocardial Fatty Acid Oxidation and Ventricular Dysfunction
To further explore the role of PGC-1 coactivators in the cardiometabolic effects of LPS, we assessed the impact of reactivating PGC-1␤ expression in cardiac myocytes during TLR4-mediated inflammatory stress. To force PGC-1␤ expression in LPS-treated cardiac myocytes, the cells were infected with an adenovirus expressing PGC-1␤ and green fluorescent protein (GFP) (Ad-PGC-1␤) or GFP alone (Ad-GFP) for 24 hours before LPS treatment. Ad-PGC-1␤infected cardiac myocytes were resistant to LPS-mediated suppression of PPAR␣, ERR␣, and FAO gene expression ( Figure 5 ). Importantly, LPS-mediated suppression of PGC-1␣ expression was preserved in Ad-PGC-1␤-infected cells, indicating that the upstream events involved in suppressing PGC-1 gene expression were unaffected by PGC-1␤ overexpression. Similarly, inflammatory cytokine expression was not attenuated; rather, it was augmented in Ad-PGC-1␤infected cells.
To extend the rescue studies to an in vivo system, we used a doxycycline-inducible, dual-transgenic mouse system to force expression of PGC-1␤ specifically in cardiac myocytes (TRE-PGC-1␤ MHCrtTA mice 23 ). For these experiments, nontransgenic and TRE-PGC-1␤ MHCrtTA mice were given doxycycline-containing chow 48 hours before PBS or LPS injection. In hearts of nontransgenic mice, LPS led to profound downregulation of PGC-1␤ mRNA levels. As expected, myocardial expression of PGC-1␤ in TRE-PGC-1␤ MHCrtTA mice was induced Ϸ6to 7-fold and the expression level was unaffected by LPS. Myocardial PGC-1␣ gene expression was equally suppressed by LPS treatment in both nontransgenic and TRE-PGC-1␤ MHCrtTA mice ( Figure  6 ). Interestingly, the suppression of PGC-1 gene targets by LPS was largely reversed by induction of PGC-1␤ ( Figure 6 ). Notably, LPS-mediated induction of inflammatory gene expression (TNF␣, iNOS, and IL-6) occurred to comparable or greater levels in TRE-PGC-1␤ MHCrtTA mice relative to nontransgenic animals (online-only Data Supplement Figure 3) . These results provide further evidence that downregulation of the PGC-1 circuit is a critical metabolic event downstream of TLR4-mediated inflammation. To assess the metabolic consequences of PGC-1␤ induction in the setting of LPS stimulation, myocardial palmitate oxidation rates were determined in hearts isolated from nontransgenic and TRE-PGC-1␤ MHCrtTA mice treated with LPS or PBS. In nontransgenic mice, we observed the expected decline in FAO rates with LPS treatment. In contrast, TRE-PGC-1␤ MHCrtTA animals were protected from this effect ( Figure 7A ). The LPSmediated increase in myocardial triglyceride accumulation was also reduced by Ϸ50% in TRE-PGC-1␤ MHCrtTA mice. Importantly, serum lipid levels were similar in nontransgenic and TRE-PGC-1␤ MHCrtTA mice, demonstrating that the re-duction in myocardial triglyceride is not a consequence of altered lipid delivery to the heart ( Figure 7B ).
To investigate whether cardiac myocyte expression of PGC-1␤ modulates cardiac contractile function during LPSinduced inflammatory stress, echocardiography was performed on nontransgenic and TRE-PGC-1␤ MHCrtTA mice after LPS injection. PGC-1␤ overexpression by itself did not produce structural or functional cardiac abnormalities as illustrated in the PBS control mice (Table and Figure 8A and 8B). Nontransgenic mice (FVB) injected with LPS had a significant decline in cardiac function, as evidenced by a reduction in left ventricular fractional shortening (52.6Ϯ0.6% to 24.0Ϯ1.3%). These results were similar to those seen with C57BL/6 mice ( Figure 1B) , except the baseline anesthesia effects on cardiac function are more pronounced in the C57BL/6 strain. In striking contrast, TRE-PGC-1␤ MHCrtTA mice exhibited only a modest decrease in cardiac function compared with PBS-injected littermates (50.8Ϯ1.2% versus 37.9Ϯ0.9%; Table and Figure 8A and 8B) . In addition to enhancing mitochondrial function and metabolism, PGC-1 coactivators can induce the expression of reactive oxygen species (ROS) scavengers. 29 The generation of ROS in the myocardium occurs rapidly after LPS administration and is linked to myocardial dysfunction. 15, 30, 31 To assess the effects of PGC-1␤ overexpression on myocardial oxidative stress after LPS injection, we determined tissue levels of reduced glutathione (GSH) in nontransgenic and TRE-PGC-1␤ MHCrtTA mice after PBS or LPS injection. As shown in Figure 8C , LPS caused a drop in myocardial GSH levels 6 hours after injection, consistent with increased levels of oxidative stress. In contrast, LPS did not induce a decrease in myocardial GSH levels in transgenic animals. The mRNA expression of ROS scavengers known to be influenced by PGC-1 revealed that the mitochondrial enzyme superoxide dismutase (SOD)2 was upregulated in TRE-PGC-1␤ MHCrtTA mice ( Figure 8D) . These data suggest that in addition to their metabolic effects, the PGC-1 coactivators probably influence oxidative stress levels in the myocardium.
Discussion
Sepsis is a common clinical disease characterized by widespread inflammation and end-organ dysfunction. The heart is frequently involved in this syndrome and contributes to the likelihood of death. At present, there are no effective therapies to improve myocardial function during sepsis. TLR4 plays a key role in initiating the inflammatory response during Gram-negative bacteremia by stimulating the production of NF-Bdependent cytokines. Attempts to treat sepsis by preventing upstream activation of TLR4 and/or cytokine signaling have been largely unsuccessful in patients. 32 Therefore, identification of potential targets downstream of the inflammatory response is of significant interest. Sepsis is known to diminish oxidative metabolism in the heart and other tissues, 2 suggesting that targeting inflammatory-metabolic "cross-talk" could improve outcome in this syndrome. Herein, we describe a cascade of events that links TLR4 activation to myocardial metabolism through downregulation of PGC-1 coactivators.
Previous studies have reported variable effects of LPS on cardiac fuel and energy metabolism. 33, 34 Using an isolated working heart system, we demonstrated that LPS led to a consistent decrease in palmitate oxidation rates compared with controls. Together with an increase in circulating lipids, the reduction in myocardial capacity for fat oxidation promotes the development of myocardial steatosis, a pathological finding also observed in the hearts of humans with sepsis. 4 -6,35 Consistent with these findings, TLR4 was recently shown to mediate a similar fuel utilization shift in human primary skeletal muscle cells in culture. 36 The presence of increased myocardial lipids normally triggers a compensatory increase in the transcriptional activity of PPAR␣ and ERR␣ and the expression of their coactivators PGC-1␣ and PGC-1␤, leading to an increase in capacity for FAO. 7 However, in our system, LPS diminished myocardial FAO rates despite an elevation in plasma lipids, suggesting a direct effect of inflammation on the machinery that regulates FAO enzyme expression. To determine the mechanism by which LPS alters myocardial metabolism, we initially focused our investigation on PGC-1␣ and PGC-1␤, given their ability to "boost" the activity of several transcription factors that regulate mitochondrial FAO. Previous studies have demonstrated both upregulation and downregulation of PGC-1 coactivator expression during inflammation, which may be related to the kinetics of the PGC-1 response and/or the model of systemic inflammation. 8, 16, 37 The data presented herein provide strong evidence that the PGC-1 axis is deactivated in the cardiac myocyte early after LPS stimulation. Specifically, the expression of PGC-1␣ and PGC-1␤ was reduced by LPS in cardiac myocytes in vivo and in culture. Furthermore, LPS decreased the expression of known PGC-1 gene targets with a pattern similar to that of PGC-1deficient hearts. 13 Interestingly, this gene expression profile is reminiscent of that seen in other forms of heart failure. Importantly, activation of TLR4 in cardiac myocytes, where the systemic effects of LPS are removed, still triggered the downregulation of PGC-1␣/␤ and their target genes, thereby confirming the direct relationship between these inflammatory signaling-metabolic events.
The suppression of PGC-1␣ gene expression by LPS was found to occur at least in part at the transcriptional level. Moreover, blocking the TLR4:NFB axis prevented the downregulation of PGC-1 coactivator expression by LPS. We excluded AMPK, a known activator of PGC-1␣, 10 as well as TNF␣, IL-6, and NO as mediators of LPS-induced suppression of PGC-1 gene expression. Whether NF-B directly mediates the suppression of PGC-1 gene transcription, as has been recently proposed, 38 or acts indirectly through the production of another molecule is an area of active investigation.
The conflicting data surrounding the effects of sepsis and LPS on the expression and activity of PGC-1 coactivators have been confounded in part by the lack of corroborative functional and physiological studies. To determine whether the suppression of myocardial FAO triggered by LPS:TLR4 signaling requires deactivation of the PGC-1 axis, we used PGC-1␤ gain-of-function strategies. Forced PGC-1␤ expression in cardiac myocytes in culture and in vivo reversed the suppression of FAO/mitochondrial gene expression induced by LPS. Importantly, reactivation of PGC-1␤ did not alter the induction of upstream inflammatory mediators or the downregulation of the related coactivator, PGC-1␣, after LPS challenge. To validate the physiological relevance of these gene expression changes, we demonstrated that forced PGC-1␤ expression protected mice from LPS-induced suppression of mitochondrial FAO. Consistent with this finding, myocyte triglyceride accumulation was significantly decreased after LPS stimulation in TRE-PGC-1␤ MHCrtTA compared with nontransgenic mice despite similar increases in the levels of circulating lipids. That the LPS-mediated downregu- lation of PGC-1␣ is still observed in TRE-PGC-1␤ MHCrtTA mice argues that the rescue of metabolism by PGC-1␤ is not a secondary consequence of disrupting upstream cytokine signaling or improving cardiac function. Although the use of a nonphysiological overexpression system to deliver PGC-1␤ is a limitation of this model, it serves as an important proof-of-concept experiment for future efforts toward targeting this gene regulatory circuit as a therapeutic strategy. Myocardial dysfunction is a common and important finding in patients with sepsis, yet there are currently no therapies directed toward improving cardiac function in this syndrome. 39 In the present study, we demonstrate that cardiac myocyte-specific PGC-1␤ overexpression leads to significantly improved cardiac function after LPS treatment. The mechanistic basis for this finding probably is multifactorial but may relate to the normalization of metabolic derangements and/or a reduction in oxidative stress levels. Previous studies have demonstrated that LPS injection rapidly triggers ROS generation in the myocardium 15, 30 and PGC-1 coactivators regulate the expression of several ROS scavenging enzymes. 29, 40 Consistent with this, we observed an increase in ROS with LPS that was reversed by PGC-1␤ overexpression. Gene expression analysis revealed that of the PGC-1 ROS scavenger targets, only SOD2 was significantly modulated with PGC-1␤ overexpression. Thus, PGC-1 appears to influence oxidative stress generation in addition to modulating metabolism in response to inflammatory stress. These findings, combined with evidence that "recovery" of PGC-1 expression in human patients with sepsis is predictive of survival, suggest that strategies to target PGC-1 expression/ activity in cardiac myocytes may prove to be a novel therapeutic approach for the prevention and treatment of sepsis-induced cardiac dysfunction. 41 Moreover, the suppression of PGC-1 expression by inflammatory signals may be a common theme in more diverse forms of heart failure.
